Prolonged immunodeficiency after allogeneic bone marrow transplantation (BMT) results in significant morbidity and mortality from infections, especially in adult recipients of an HLA-matched unrelated graft. Strategies to overcome post-transplant immunodefi-ciency could not only decrease the incidence of post-transplant infections, but could also enhance post-transplant cancer immunotherapy, including graft-versus- tumor activity, tumor vaccines or cellular therapies. We propose to study in well-defined and clinically relevant murine BMT models the effects of cytokine therapy with interleukin-7, Insulin Growth Factor-I, Keratinocyte Growth Factor, and/or Thymic Stromal Lymphopoietin on immune reconstitution. We will compare immune reconstitution in young and middle-aged patients, recipients of MHC-matched or MHC-mismatched allogeneic BMT, and recipients of allogeneic BMT with or without graft-versus-host-disease (GVHD).
In Specific Aim 1 we propose to analyze the effects of the administration of immunostimulatory cytokines on thymic and peripheral immune reconstitution after allogeneic BMT. We will perform a sequential analysis by flow cytometry and histology of the development of: (a) donor-derived cells in bone marrow, blood and lymphoid organs, (b) thymic positive and negative selection, (c) thymic architecture, (d) T-cell repertoire, and (e) peripheral T-cell homeostasis. Our analysis will focus specifically on T and B cell and dendritic cell development.
In Specific Aim 2 we propose to study the effects of immunostimulatory cytokine administration on the development of GVHD morbidity, mortality and specific GVHD-associated organ pathology after allogeneic BMT. The spefici effects on the pathophysiology of GVHD will be assessed: (a) donor T-cell expansion and activiation, (b) CD4/8 ratio, (c) serum cytokine levels and intracellular cytokine expression, and (d) macrphage activation.
In Specific Aim 3 we propose to study the effects of immunostimulatory cytokine administration on B and T-cell function in in vitro and in vivo assays. This will include an analysis of the effects on antimicrobial activity against Listeria in vivo and on graft-versus-tumor (GVT) activity of donor T-cells in several murine GVT models, including a model for donor leukocyte infusion (DLI). These studies can contribute to a better understanding of the severe post-transplant immunodeficiency and to the development of immunostimulatory cytokines as novel strategies to enhance post-transplant immune reconstitution without aggravating GVHD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA023766-24A1
Application #
6606696
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-08
Project End
2007-02-28
Budget Start
Budget End
Support Year
24
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239

Showing the most recent 10 out of 452 publications